Images List Premium Download Classic

Receptor

Receptor-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Conductive support, electrophotographic photoreceptor, and process cartridge
Fuji Xerox Co., Ltd.
June 14, 2018 - N°20180164707

A conductive support is formed of a bottomless hollow cylindrical member being made of metal and having a thickness t of equal to or less than 0.5 mm, the conductive support including: a chamfer portion on an outer peripheral surface side of at least one end of the conductive support over an entire circumferential direction, wherein the chamfer portion has a ...
Anti-gitr antibodies for cancer diagnostics
Bristol-myers Squibb Company
June 14, 2018 - N°20180164321

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (gitr). Such antibodies are useful for methods of detecting the expression of gitr in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-gitr immunotherapy or predicting whether a cancer patient will respond to anti-gitr immunotherapy..
Novel t cell receptors and immune therapy using the same
Immatics Biotechnologies Gmbh
June 14, 2018 - N°20180164315

The present invention relates to antigen recognizing constructs against a tumor associated antigen (taa) derived from the target protein ddb1 and cul4 associated factor 4-like 2 (dcaf4l2). The invention in particular provides novel t cell receptor (tcr) based molecules which are selective and specific for the taa of the invention.
Receptor Patent Pack
Download 2409+ patent application PDFs
Receptor Patent Applications
Download 2409+ Receptor-related PDFs
For professional research & prior art discovery
inventor
  • 2409+ full patent PDF documents of Receptor-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Sensor for detection of analytes
Case Western Reserve University
June 14, 2018 - N°20180164240

A sensor for the detection of an analyte in a fluid includes an electrode having a detection surface, a polydopamine layer adhered to the electrode detection surface; and optionally a receptor chemically functionalized to the polydopamine of the detection surface of the electrode. The receptor selectively binds to the analyte of interest and the analyte once bound is detectable by ...
Compositions and methods for controlling vasculature
Yale University
June 14, 2018 - N°20180163210

The invention relates to compositions and methods for reducing excessive vascular development and treat related disorders. In one aspect, the invention provides methods for treating, reducing or inhibiting vascular development in a subject in need thereof.
Alk4:actriib heteromultimers and uses thereof
Acceleron Pharma Inc.
June 14, 2018 - N°20180163187

In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an alk4 receptor and an extracellular domain of actriib. In certain aspects, such soluble alk4:actriib complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells.
Receptor Patent Pack
Download 2409+ patent application PDFs
Receptor Patent Applications
Download 2409+ Receptor-related PDFs
For professional research & prior art discovery
inventor
  • 2409+ full patent PDF documents of Receptor-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Aflatoxin templates, molecularly imprinted polymers, and methods of making and using the same
Alltech, Inc.
June 14, 2018 - N°20180163011

Molecularly imprinted polymers (mips) are materials exhibiting molecular recognition of a target molecule. Mips are synthesized in the presence of an aflatoxin template, a mimic to the targeted molecule, used as an imprint that is further washed away with suitable solvent after completion of the polymerization process, leaving a cavity in the polymer of the same stereochemistry, functionality and morphology ...
Chimeric antigen receptors (cars), compositions and methods thereof
Icell Gene Therapeutics Llc
June 14, 2018 - N°20180162939

The present disclosure provides chimeric antigen receptors, compostions, and methods thereof. In one embodiment the present disclosure provides a method of treating autoimmune diseases, asthma, and preventing or mediating organ rejection in a subject..
Antibodies against the rgm a protein and uses thereof
Abbvie Inc.
June 14, 2018 - N°20180162933

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize rgm a protein. Specifically, these antibodies have the ability to inhibit the binding of rgm a to its receptor and/or coreceptors.
Inhibitors of type 2 vascular endothelial growth factor receptors
Bristol-myers Squibb Company
June 14, 2018 - N°20180162926

The present disclosure relates to novel vascular endothelial growth factor receptor (vegfr)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (vegfs). The present disclosure also provides various improvements relating to single domain binding polypeptides..
Fusion polypeptides capable of activating receptors
Regeneron Pharmaceuticals, Inc.
June 14, 2018 - N°20180162924

A fusion polypeptide comprising (a)x-m-(a′)y, wherein a and a′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor.
B1sp fusion protein therapeutics, methods, and uses
The University Of British Columbia
June 14, 2018 - N°20180162923

Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a b1sp fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer.
T cell receptors with improved pairing
Immatics Biotechnologies Gmbh
June 14, 2018 - N°20180162922

The present invention relates to modified t cell receptor (tcr) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the imgt numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.. .
Receptor Patent Pack
Download 2409+ patent application PDFs
Receptor Patent Applications
Download 2409+ Receptor-related PDFs
For professional research & prior art discovery
inventor
  • 2409+ full patent PDF documents of Receptor-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Multivalent regulatory t cell modulators
Delinia, Inc.
June 14, 2018 - N°20180162919

This disclosure provides compounds that contain an il-2 receptor-binding moiety and an st2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an il-2 receptor-binding moiety and an st2-binding moiety..
Recombinant proteins and their therapeutic uses
Bioven 3 Limited
June 14, 2018 - N°20180162917

A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within ...
Cytokine
London School And Hygiene And Tropical Medicine
June 14, 2018 - N°20180162912

A novel cytokine, u83a, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and hiv/aids, are described..
Heterocyclic compound and use thereof
June 14, 2018 - N°20180162875

Wherein each symbol is as defined in the specification, or a salt thereof, which has an ampa (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, alzheimer's disease or attention deficit hyperactivity disorder (adhd) and the like..
Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
Duquesne University Of The Holy Ghost
June 14, 2018 - N°20180162863

The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders..
2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
Takeda Pharmaceutical Company Limited
June 14, 2018 - N°20180162850

The present invention provides a compound having a cholinergic muscarinic m1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for alzheimer's disease, schizophrenia, pain, sleep disorder, parkinson's disease dementia, dementia with lewy bodies and the like. The present invention relates to a compound represented by the formula (i) or a salt thereof: wherein ...
Non-selective kinase inhibitors
Gilead Sciences, Inc.
June 14, 2018 - N°20180162837

Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (rtk) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of rtks associated with vascular and pulmonary disorders..
2-(2,4,5-substituted-anilino)pyrimidine compounds
Astrazeneca Ab
June 14, 2018 - N°20180162832

The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the l858r activating mutant, the exon19 deletion activating mutant and the t790m resistance mutant). Such compounds ...
Loading